V. Vendrely

Hôpital Cardiologique du Haut-Lévêque

Papers

1

Total Citations

14

H-Index

1

About

Dr. V. Vendrely is a leading surgical oncologist whose research focuses on optimizing treatment strategies for rectal cancer, particularly through the integration of neoadjuvant therapies and minimally invasive techniques. Her most notable contribution is the GRECCAR 2 randomized phase 3 trial, which compared local excision versus total mesorectal excision in patients with T2-T3 low rectal cancer who demonstrated a good response after neoadjuvant radiochemotherapy. This landmark study, published in 2014 and cited 14 times, provided critical preliminary evidence that organ-preserving approaches could be safely considered in carefully selected patients, challenging the standard of radical surgery and improving quality of life. Dr. Vendrely’s work sits at the intersection of surgical precision and personalized oncology, helping to refine risk stratification and expand the role of sphincter-sparing procedures. Her research has influenced clinical guidelines and sparked further investigation into non-operative management of rectal cancer. Through rigorous trial design and patient-centered outcomes, she continues to shape the evolving landscape of colorectal cancer care.

Research Focus

Key Achievements

1
H-Index
1
Papers
14
Total Citations
14
Avg Citations/Paper
🏆 Most Cited Paper
Local Excision Versus Total Mesorectal Excision in Patients with Good Response After Neoadjuvant Radiochemotherapy for T2-T3 Low Rectal Cancer: Preliminary Results of the GRECCAR 2 Randomized Phase 3 Trial
14 citations · 2014
📈 Most Prolific Year: 2014 (1 Papers)
🤝 Key Collaborators: 18
🏛 Institutions: Hôpital Cardiologique du Haut-Lévêque

Top Papers

  1. 1

Key Collaborators

Contact & Links

Available for collaboration
Content generated · 11 days ago